VIENNA, Austria and BUDAPEST, Hungary, May 12, 2026 / Biotech Newswire / -- AOP Health, a global pharmaceutical enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership with VRG Therapeutics, an AI-driven developer for miniproteins based in Budapest. The collaboration aims to advance a novel Kv1.3 potassium channel inhibitor, a key regulator of immune cell activity, for use in inflammation and immunology (I&I) indications.
The collaboration centers on a next-generation miniprotein candidate discovered using VRG Therapeutics’ AI-MPRO platform, an AI-based system to design and test new miniproteins. This platform combines AI-driven protein design with experimental validation to generate highly selective, target-specific miniproteins.
Kv1.3 is a clinically validated ion channel that plays a key role in regulating pathogenic immune cell activity in chronic inflammatory and autoimmune diseases. Selective inhibition of Kv1.3 has long been considered a promising strategy to modulate disease-driving immune responses while minimizing broader immunosuppression. The partners aim to leverage the precision and selectivity of the miniprotein modality to address limitations seen in previous therapeutic approaches targeting this pathway.
Under the agreement, the partners will generate additional preclinical proof-of-concept data across selected indications to support progression toward first-in-human studies.
The collaboration brings together VRG Therapeutics’ AI-driven discovery platform with AOP Health’s three decades of experience in developing therapies for high unmet medical need. It also expands AOP Health’s external R&D activities further into immunology, a scientifically complex and rapidly evolving therapeutic area.
For VRG Therapeutics, the partnership provides important validation of the AI-MPRO platform and supports the translation of its technology toward clinical application. For AOP Health, it strengthens its pipeline through access to a novel modality with potential for high target precision.
“VRG’s AI-MPRO platform has demonstrated the ability to generate highly selective candidates against complex biological targets,” said Martin Steinhart, CEO of AOP Health Group. “We see strong potential in targeting Kv1.3 for autoimmune and inflammatory diseases and look forward to advancing this program toward clinical evaluation.”
“With its established development capabilities and strong track record in addressing unmet medical needs, AOP Health is an ideal partner for this program.” commented Zalán Péterfi, Chairman of the Board and Managing Director at VRG Therapeutics. “Advancing together the Kv1.3 program, we intend to expand our partnership to fully exploit the platform potential.”
